Skip to content

Moderna’s Concerns About Omicron Outlook Spark Market Slump

  • One founder says the mutations point to ‘serious threat’
  • CEO Stephane Bancel spooks markets with comments to FT
Video player cover image
WATCH: Moderna co-founder Noubar Afeyan discusses omicron and the process of developing a new targeted vaccine.Source: Bloomberg
Updated on

Moderna Inc.’s top executives reiterated that the omicron variant’s many mutations suggest new vaccines will be needed, triggering a drop in financial markets. 

“The number of mutations on this virus are surprising,” co-founder Noubar Afeyan said in a Bloomberg Television interview.  “We have to take it for the serious threat that it poses.”